Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...

Ramez Al Khayyat, President of UCC Holding, shares how the company has grown into a global player, the mindset behind its ...